Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 15 articles: HTML format

Single Articles

June 2025
1. JIANG F, Guan CL, Jiao LZ, Xu T, et al
   Efficacy and Safety of Biweekly Single-Dose Actinomycin D vs Multiday Methotrexate in Low-Risk Gestational Trophoblastic Neoplasia: A Prospective Multicenter Randomized Trial.
   Ann Oncol. 2025 Jun 19:S0923-7534(25)00811-7. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
2. MAYADEV J, Vazquez Limon JC, Ramirez Godinez FJ, Leiva M, et al
   Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.
   Ann Oncol. 2025 Jun 2:S0923-7534(25)00738-0. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   May 2025
3. HARDY-BESSARD AC, Pujade-Lauraine E, Moore RG, Montestruc F, et al
   Dostarlimab and niraparib in primary advanced ovarian cancer.
   Ann Oncol. 2025 May 30:S0923-7534(25)00201-7. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   
4. HUIS IN 'T VELD EA, Van Assche IA, Van Calsteren K, Salaets T, et al
   LONG-TERM DEVELOPMENT OF 12- AND 15-YEAR-OLD OFFSPRING AFTER MATERNAL CANCER DIAGNOSIS DURING PREGNANCY: A PROSPECTIVE MULTICENTRE COHORT STUDY.
   Ann Oncol. 2025 May 6:S0923-7534(25)00171-1. doi: 10.1016/j.annonc.2025.
   PubMed     Abstract available
   
   
   March 2025
5. CHAMBERS LM, Eskander RN, O'Malley DM
   Targeting the future: Antibody-Drug Conjugates (ADCs) in platinum-sensitive ovarian cancer in the post-PARP era.
   Ann Oncol. 2025;36:244-246.
   PubMed    
   
   
   November 2024
6. SECORD AA, Lewin SN, Murphy CG, Cecere SC, et al
   The Efficacy and Safety of Mirvetuximab Soravtansine in FRalpha-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.
   Ann Oncol. 2024 Nov 29:S0923-7534(24)04948-2. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
7. HARTER P, Marth C, Mouret-Reynier MA, Cropet C, et al
   Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
   Ann Oncol. 2024 Nov 9:S0923-7534(24)04907-X. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   
8. LORUSSO D, Fuca G
   KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer?
   Ann Oncol. 2024;35:925-927.
   PubMed    
   
   
   October 2024
9. LORUSSO D, Colombo N, Dubot C, Caceres MV, et al
   Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study.
   Ann Oncol. 2024 Oct 9:S0923-7534(24)04033-X. doi: 10.1016/j.annonc.2024.
   PubMed     Abstract available
   
   
   September 2024
10. MONK BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, et al
    Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Ann Oncol. 2024 Sep 14:S0923-7534(24)03762-1. doi: 10.1016/j.annonc.2024.08.2241
    PubMed     Abstract available
    
    
    August 2024
11. VAN GORP T, Cibula D, Lv W, Backes F, et al
    ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer.
    Ann Oncol. 2024 Aug 23:S0923-7534(24)03822-5. doi: 10.1016/j.annonc.2024.08.2242
    PubMed     Abstract available
    
    
    
12. COLOMBO N, Caruso G, Jalving M
    Immune Checkpoint Inhibitors in Endometrial Cancer: A Cinderella Story.
    Ann Oncol. 2024;35:686-688.
    PubMed    
    
    
    June 2024
13. POWELL MA, Bjorge L, Willmott L, Novak Z, et al
    Overall Survival in Patients with Endometrial Cancer Treated with Dostarlimab plus Carboplatin-Paclitaxel in the Randomized ENGOT-EN6/GOG-3031/RUBY Trial.
    Ann Oncol. 2024 Jun 10:S0923-7534(24)00721-X. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    May 2024
14. PIGNATA S, Califano D, Lorusso D, Arenare L, et al
    MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy.
    Ann Oncol. 2024 May 2:S0923-7534(24)00128-5. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    
    February 2024
15. BOGANI G, Monk BJ, Powell MA, Westin SN, et al
    Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
    Ann Oncol. 2024 Feb 29:S0923-7534(24)00056-5. doi: 10.1016/j.annonc.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.